CTRI/2024/02/062362Not yet recruitingNot Applicable
Disability in Rheumatoid Arthritis Patients: Patients perspective
All India Institute of Medical Sciences Guwahati1 site in 1 country150 target enrollmentStarted: February 20, 2024Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- prevalence of disability in terms of HAQDI Score
Study Overview
Brief Summary
The study aims to assess the disability in patients with rheumatoid arthritis attending PMR OPD in terms of HAQ DI score (Indian version) from the patients perspective using the Indian version of Health assessment questionnaire and disability index (HAQDI).
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18.00 Year(s) to 80.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •patients with definite rheumatoid arthritis attending PMR OPD fulfilling 2010 ACR CRITERIA.
Exclusion Criteria
- •patient aged below 18 years or more than 80 years patient with mental illness or not giving consent.
Outcomes
Primary Outcomes
prevalence of disability in terms of HAQDI Score
Time Frame: Baseline
Secondary Outcomes
- usefulness of Patient reported outcomes in disability assessment in RA patients(baseline)
Investigators
Dr Satyaranjan Sethi
All India Institute of Medical Sciences Guwahati
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Mobile application to monitor the disease activity of Rheumatoid arthritisCTRI/2025/09/095021Saveetha Medial College and Hospital60
Not yet recruiting
Phase 3
To study the efficacy of homoeopathy in management of rheumatoid arthritisCTRI/2026/01/101901Dr Preeti Lamba200
Recruiting
Phase 4
To check the effectiveness of study drug in rheumatoid arthritis participantsCTRI/2025/10/095727Eutherva Medicament Pvt. Ltd24
Recruiting
Phase 2/3
The effect of Mud Lepa in rheumatoid arthritisCTRI/2024/05/067340National Institute of Ayurveda60
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT07276581AstraZeneca320